Author: Andrew Miklos

Headshot of Andrew Miklos.

Andrew, who trained in biochemistry and biophysics, is a branch chief in the Division of Data Integration, Modeling, and Analytics. He oversees analysis and evaluation of NIGMS programs and processes, as well as creation of tools to provide Institute staff with the data needed to make informed decisions.

Posts by Andrew Miklos

A Closer Look at the NIGMS AREA (R15) Program


Continuing our regular posts detailing funding trends for NIGMS programs, here we provide a closer look at the NIGMS Academic Research Enhancement Awards (AREA) R15 program. AREA grants support small-scale research projects involving primarily undergraduate students at institutions that received no more than $6 million in funding from NIH in 4 of the past 7 years. Awards can be up to $300,000 in direct costs for the entire project period of up to 3 years. Unlike most of our other Research Project Grant (RPG) awards, which have noncompeting renewals on an annual basis, R15 funds are obligated in the first year and last the duration of the project period. Grantees can renew these awards in a competitive proposal process.

NIH offers two different R15 awards: AREA and the Research Enhancement Award Program (REAP). The key distinction between them is that AREA grants are available to undergraduate-focused institutions, while REAP grants are available to health professional and graduate schools. See the FAQs about the programs for a list of common questions. NIGMS participates in only the AREA program.

Continue reading “A Closer Look at the NIGMS AREA (R15) Program”

Funding Trends: MIRA Applications and Overall Impact Scores

1 comment

One of the most common questions we receive about the Maximizing Investigators’ Research Award (MIRA) program is the likelihood of an application’s funding given a certain overall impact score.

Frequent readers of this blog may note that we typically provide statistics as they relate to our R01 portfolio, but we’ve yet to provide a similar “funding curve” for the MIRA program. One reason that MIRA applications haven’t been included in these analyses is that, unlike most R01 applications, MIRA R35 applications don’t receive a percentile score. The percentile score allows for normalization of overall impact scores across study sections to account for any differences in scoring behavior that are observed in review panels. See the Office of Extramural Research’s comprehensive blog post for more information about overall impact scores and percentiles.

Continue reading “Funding Trends: MIRA Applications and Overall Impact Scores”

Application and Funding Trends in Fiscal Year 2017


NIGMS is committed to ensuring that taxpayers get the best possible returns on their investments in fundamental biomedical research. As part of this commitment to stewardship [PDF 7.89MB], we regularly monitor trends in our funding portfolio.

We recognize the value of a diversified investment portfolio and approach our research investments in a similar fashion. Sustaining a broad and diverse portfolio of talented investigators is a central goal of the Institute, as a wide variety of research questions can be studied by an investigator pool that comprises many different backgrounds, fields, and skills. To monitor this, we track the “cumulative investigator rate,” which indicates the proportion of unique investigators actively seeking funding who had an NIGMS grant in a given Fiscal Year (FY). As shown in Figure 1, the number of investigators seeking support consistently increased between FY 2006 and 2014, but the number of NIGMS-funded investigators remained relatively unchanged over that same period. As a result, the cumulative investigator rate steadily decreased. Since FY 2014, the cumulative investigator rate has steadily increased, as the number of applicants seeking support has stabilized and the number of investigators receiving support has grown by 14%. Currently, 37.4% of investigators seeking R01/R35 funding from NIGMS received support in FY 2017.

Figure 1. Number of NIGMS R01/R35 Applicants, Awardees, and Cumulative Investigator Rates, FY 2006-2017. The number of investigators actively seeking NIGMS R01 and R35 support (blue circles, dashed line; left axis) increased steadily from FY 2006 to 2014 but has stabilized more recently. These applicants were defined as anyone who submitted a competing NIGMS R01 or R35 application in the fiscal year shown or any of the previous four fiscal years. The NIGMS R01 and R35 awardee counts (green squares, solid line; left axis) remained relatively stable from FY 2006 to 2014 and have increased somewhat over the past three years. As a result, the NIGMS cumulative investigator rate (gray triangles, dotted line; right axis) declined from FY 2006 to 2014 but has begun to recover since then.

Continue reading “Application and Funding Trends in Fiscal Year 2017”

Stable Success Rates and Other Funding Trends in Fiscal Year 2016


NIGMS is committed to ensuring that taxpayers get the best possible returns on their investments in fundamental biomedical research. As part of an NIH-wide commitment to enhancing stewardship, we regularly monitor trends in the Institute’s funding portfolio.

One of the most commonly cited metrics when discussing grants is success rate, calculated as the number of applications funded divided by the number of applications reviewed. As shown in Figure 1, the success rate for NIGMS research project grants (RPGs) was 29.6% in Fiscal Year (FY) 2016, the same as it was in FY 2015. Although we funded a record number of competing RPGs in FY 2016, we also received more applications than in FY 2015, leading to a level success rate. The first applications and grants for the Maximizing Investigators’ Research Award (MIRA) (R35) program are included in the FY 2016 RPG counts. The increase in RPG applications in FY 2016 has reversed the downward trend noted in last year’s analysis.

Figure 1. Number of NIGMS Competing RPG Applications, Number of Funded Competing RPGs and Success Rates for RPGs, Fiscal Years 2005-2016. NIGMS RPG applications (blue circles, dashed line; left axis) increased from FY 2015-2016. NIGMS-funded RPGs (green squares, solid line; left axis) also increased from FY 2015-2016. Consequently, the NIGMS RPG success rate (gray triangles, dotted line; right axis) remained unchanged from FY 2015. The dip in success rate in FY 2013 was due in part to the budget sequester.

Continue reading “Stable Success Rates and Other Funding Trends in Fiscal Year 2016”

Outcomes Analysis of the NIGMS Institutional Research and Academic Career Development Awards (IRACDA) Program


We recently analyzed the career outcomes of scholars who participated in the NIGMS IRACDA program. A goal of this program is to provide a diverse pool of postdoctoral scholars with research and professional skills needed to be successful in academic careers. The program combines a mentored postdoctoral research experience with an opportunity to develop additional academic and teaching skills, including a teaching practicum at a partner institution that enrolls a substantial number of students from underrepresented groups. Since its inception in 1999, 25 research-intensive institutions have received IRACDA awards, which have supported more than 600 scholars.

Our assessment focused on the 450 alumni who completed their training through November 2014. Important findings include:

  • IRACDA scholars are diverse: 63% are female, and 53% identify as a race/ethnicity other than white, non-Hispanic.
  • Approximately 73% of IRACDA alumni are in academic faculty positions at a range of institutions (see Figure 1).
  • Among the scholars in faculty positions, 35% are at research-intensive institutions, 25% are at primarily undergraduate institutions and the remaining percent are at associate- and master’s degree-granting institutions. In addition, 25% of the IRACDA alumni in academic positions are faculty at a designated minority-serving institution.

Continue reading “Outcomes Analysis of the NIGMS Institutional Research and Academic Career Development Awards (IRACDA) Program”

Distribution of NIGMS R01 Award Sizes


We have published median and mean direct cost award amounts for R01 grants, but these statistical aggregates can mask variations present in our grant portfolio. In this analysis, we illuminate two major differences in R01 award size distributions: those between single-principal investigator (PI) and multiple-PI (MPI) grants and those between new and competing renewal grants. It is worth noting that the numbers are per award values rather than the total NIGMS support provided to investigators and that award size can also be influenced by NIH-wide policies and NIGMS-specific policies that promote the consideration of multiple factors in making funding decisions.

The first major distinction in NIGMS R01s exists between single-PI and MPI awards. NIH has allowed applications that identify more than one PI since Fiscal Year 2007. Many MPI applications request, and receive, larger amounts of funding than do typical single-PI applications. As shown in Figure 1, single-PI awards have a size peak in the range of $175,000-200,000 in direct costs (funds typically directly associated with the research project rather than overhead costs), while MPI awards tend to have larger budgets and a broader size distribution. MPI awards are, on average, approximately 25% larger for each additional PI (data not shown).

Continue reading “Distribution of NIGMS R01 Award Sizes”